The NovaBridge Biosciences (NBP) SEC filings page on Stock Titan provides access to the company’s official disclosures as a foreign private issuer listed on Nasdaq. NovaBridge, formerly known as I-Mab, files reports such as Form 20-F and Form 6-K that describe its financial condition, risk factors, and operational progress as a global biotechnology platform company.
In these filings, NovaBridge outlines its business model, which combines business development and translational clinical development to advance a pipeline led by givastomig, ragistomig, uliledlimab, and VIS-101. Management’s discussion and analysis sections describe how the company allocates resources to oncology and ophthalmology programs, summarizes its collaborations with partners such as ABL Bio, and explains the structure of subsidiaries like Visara within its hub-and-spoke framework.
Investors reviewing NovaBridge’s SEC reports can examine clinical development disclosures for givastomig, including its positioning as a Claudin 18.2 x 4-1BB bispecific antibody in gastric and other gastrointestinal cancers, and for ragistomig as a PD-L1 x 4-1BB bispecific in solid tumors. Filings also discuss rights to uliledlimab outside Greater China and the VIS-101 license and assignment arrangements involving Visara and Everest Medicines.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as segment descriptions, collaboration agreements, share incentive plans, and subsequent events. Users can follow new 6-K submissions for interim updates, and consult annual filings for a more comprehensive view of NovaBridge’s strategy, risk profile, and pipeline.
By using this page, investors and researchers can monitor NovaBridge’s official SEC communications in real time, while AI-generated insights help interpret complex biotech and capital markets information contained in the original documents.
NovaBridge Biosciences reported that General Counsel Lin Liwei Lorraine received a grant of 254,780 2025 Employee Share Options, each representing a right to buy American Depositary Shares at an exercise price of 1.9300 per ADS. The options expire on 2036-07-08 and relate to an equivalent number of underlying Ordinary Shares represented by ADSs. The grant vests over five years, with 40% vesting on the second anniversary of February 1, 2026 and the balance in three equal annual installments thereafter.
NovaBridge Biosciences reported that Chief Executive Officer Srishti Gupta received a grant of 3,000,000 employee share options. These options give the right to buy Ordinary Shares at an exercise price of $2.01 per ADS-equivalent and expire on July 6, 2036. The award vests in four equal annual installments beginning on the first anniversary of July 1, 2026, and Gupta now holds 3,000,000 such options directly.
NovaBridge Biosciences director and Chief Executive Officer Srishti Gupta has filed an initial statement of ownership as an insider of the company. This Form 3 filing does not list any equity transactions or derivative positions and provides no reportable holdings or recent trades for this insider.
NovaBridge Biosciences senior executive Xu Cong Claire reported option exercises and a share sale. On July 4, 2026, she exercised derivative awards, converting 5,405 Restricted Share Units, represented by 5,405 American Depositary Shares (ADSs), into 12,432 Ordinary Shares at a conversion price of $0.00 per share.
On July 6, 2026, she completed an open-market sale of 4,485 Ordinary Shares at an average price of $0.89 per share, equivalent to an ADS sales price of $2.04. Following these transactions, she directly holds 298,101 Ordinary Shares, which the filing states are represented by 129,609 ADSs.
NovaBridge Biosciences director Fu Wei received equity-based compensation awards. On June 29, 2026, Fu Wei was granted 1,010,100 Restricted Share Units, each representing a contingent right to receive one American Depositary Share (ADS). These RSUs vest in equal annual installments on June 29, 2027 and June 29, 2028.
On the same date, Fu Wei was also granted three tranches of 2025 Employee Share Options covering 1,087,720, 1,087,720 and 725,140 underlying Ordinary Shares at an exercise price of $2.45 per share, expiring on June 29, 2036. Each option tranche vests, if at all, in eight equal quarterly installments after the issuer’s ADS 30-trading-day weighted average price reaches $8.00, $12.00 and $16.00, respectively.
NovaBridge Biosciences is implementing a major leadership transition. The company appointed Srishti Gupta, MD MPP as Chief Executive Officer and board member, effective July 1, 2026, succeeding Xi-Yong (Sean) Fu, who resigns as CEO and director on June 30, 2026 but will remain as an advisor during the transition.
Dr. Gupta is an experienced physician-executive and former CEO of Idorsia Pharmaceuticals, with nearly two decades in biopharma, global health, and strategy, including a long tenure at McKinsey & Company. As CEO, she plans to advance givastomig toward registration, expand the Visara-led ophthalmology franchise around VIS-101, and build strategic partnerships.
The filing also notes additional changes: two directors, Emmett T. Cunningham Jr. and Sean Cao, will resign from the board on June 30, 2026, with Dr. Cunningham joining the Scientific Advisory Board, and President Mark Hagler will step down from that role on July 1, 2026 while continuing as Chief Commercial Officer.
NovaBridge Biosciences director and Chief Business Development Officer Cao Sean Wuxiong received new equity awards. He was granted 181,290 employee share options to buy Ordinary Shares (via American Depositary Shares) at an exercise price of $1.53 per ADS, expiring on June 22, 2036. These options vest in eight equal quarterly installments only after the 30-trading-day weighted average price of the company’s ADS is at or above $8.00.
He also received 181,280 restricted share units, each representing a contingent right to receive one ADS. These RSUs vest over four years, with one-fourth vesting on September 3, 2026 and the remainder vesting ratably over the following 12 quarters.
NovaBridge Biosciences Chief Medical Officer Dennis Phillip Andrew reported a combination of option activity and share sales. He sold 8,494 Ordinary Shares in an open-market sale at $0.66 per share and, the prior day, exercised derivative awards into 10,302 Ordinary Shares represented by American Depositary Shares (ADSs). Following these transactions, he directly held 157,941 Ordinary Shares and 82,422 Restricted Share Units (RSUs), which each represent a right to receive one ADS.
NovaBridge Biosciences filed Amendment No. 1 to its Form 20-F to correct previously reported beneficial ownership information. The company states that these corrections do not affect its audited financial statements. Updated data show 265,377,891 ordinary shares outstanding as of December 31, 2025 and 265,991,561 shares outstanding as of March 24, 2026.
The amendment refreshes ownership details for directors, executives and major holders, including stakes held through American depositary shares and affiliated investment entities, while confirming the company is not aware of any arrangement that may result in a change of control.
NovaBridge Biosciences changed its independent auditor after the Audit Committee dismissed PricewaterhouseCoopers LLP and appointed Deloitte Touche Tohmatsu Certified Public Accountants LLP, both actions effective June 16, 2026. PwC’s audit reports for the years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications regarding uncertainty, scope, or accounting principles.
The filing notes there were no disagreements with PwC on accounting, disclosure, or audit procedures, and no reportable events other than previously disclosed material weaknesses in information technology general controls as of December 31, 2025 and 2024. NovaBridge also states it did not consult Deloitte on accounting or audit issues before the appointment. This 6-K is incorporated by reference into the company’s existing Form F-3 and multiple Form S-8 registration statements.